Podcasts about mounjaro

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

Producer Jess is back with the Recap of the Week with all the best (and so many of the worst) moments of the show! Wippa claims that he would be classified as a "bear" if he was a part of the gay community, Mounjaro has some potential new side effects that has Wippa sweating a bit and we are OBSESSED with this live performance from Jessie J!See omnystudio.com/listener for privacy information.

Are you struggling to lose weight with hypothyroidism or Hashimoto's—even when you're doing everything right?In this episode of My Thyroid Health, we take a deep dive into two powerhouse supplements: NAD+ and glutathione. These cellular-level nutrients are best known for their anti-aging and detoxifying effects, but they may also play a key role in boosting energy, improving thyroid function, and supporting weight loss—especially for thyroid patients.We also explore how combining NAD+ and glutathione with GLP-1 medications like Ozempic, Wegovy, or Mounjaro could enhance results for those struggling with metabolic resistance due to hypothyroidism. But is it safe? And what do thyroid patients need to know before starting?If you've been searching for new solutions to help with fatigue, inflammation, or a slow metabolism, this is the episode for you.Need more information? Learn more at the Paloma Health blog:Glutathione Benefits for Better Thyroid Healthhttps://www.palomahealth.com/learn/glutathione-benefits-thyroid-health The Health Benefits of NAD+https://www.palomahealth.com/learn/health-benefits-nad About Paloma Health:⁠⁠Paloma Health ⁠⁠⁠⁠⁠⁠⁠⁠is an online medical practice focused exclusively on treating hypothyroidism. From online visits with your provider to easy prescription management and lab orders, we create personalized treatment plans for you. Become a member⁠, or try our at-home test kit and experience a whole new level of hypothyroid care. Use code PODCAST to save $30 at checkout.Disclaimer: The $30 discount is only valid for first-time Paloma Health members and test kit users. Coupon must be entered at the time of checkout. Become a Paloma Member:https://www.palomahealth.com/pricing-hypothyroidism Paloma Complete Thyroid Blood Test Kit:https://www.palomahealth.com/home-thyroid-blood-test-kit

In this episode of the Irresistible You podcast, we're talking about the importance of finding your soul snack—something that feeds your soul so you're not constantly turning to food for comfort. Since Chuy passed away, my nights have felt painfully quiet. He was my constant companion during the late-night hours when the house finally settled. That kind of loss leaves a void, but here's the thing… I didn't slip back into emotional eating, and that's because I already had the Irresistible You framework to guide me.One of the most powerful tools in that framework? Feed Your Soul.Lately, diamond painting has been helping me fill that space with peace instead of food. Let's talk about why you need a soul snack and how to find one that works for you.If you've ever reached for food when what you really needed was something deeper, this episode is for you.

I'm not here to bash weight loss meds. But I am here to say the quiet part out loud. In this episode, I'm pulling back the curtain on GLP-1s like Ozempic, Wegovy, and Mounjaro—and telling you what most “experts” are too scared to say.   This isn't about judgment. I've been there. I've popped pills and prayed they'd shrink me into someone I could finally love. But here's the deal: weight loss shots may shrink your appetite, but they don't shrink the reasons you overeat. If you're not working on your mindset and identity, you're just renting results—and the rent is due the minute the meds stop.   I'll break down what the research says, what the Facebook groups aren't telling you, and the powerful truth about emotional eating, identity transformation, and how to finally lose weight in a way that lasts forever. Yes, even in your perimenopause era. What You'll Learn in This Episode: The real reason most women regain weight after stopping GLP-1s (it's not just biology) Why weight loss meds don't fix emotional eating—and what actually does How “Motivational Meltdown” keeps you stuck in a loop (and how to stop it) Why your old identity will sabotage your new body (unless you do this) The simple, repeatable process I teach my clients to stop dieting forever ================================== FEATURED ON THE SHOW / RESOURCES Quiz: What's Your Sneaky Self-Sabotage Pattern? Get my weekly emails: jenniferdent.com/emailclub Website: JenniferDent.com Instagram: @jenniferdentbrown Book your Tea Chat with Jennifer: jenniferdent.com/tea Live Event in Philadelphia: Purchase a Ticket for Cocktails & Clarity: A Wellness Happy Hour The Natural Xpression Medical Spa @thechefkenny

I avsnitt 172 av Hälsoveckan by Tyngre diskuterar Jacob och Erik ny data från Eli Lilly om har jämfört deras fetmamedicin Mounjaro mot Novo Nordisk medicin Wegovy, ofta också kallad Ozempic. Det här är den första studien där medicinerna jämförs direkt mot varandra och resultatet visade på en klar fördel för Mounjaro. Erik var under förra veckan också på en stor fetmakonferens där han fick höra om fler resultat från studien som inte fanns med i den publicerade artikeln. På Hälsoveckan by Tyngres instagram kan du hitta bilder relaterat till detta och tidigare avsnitt. Hålltider (00:00:00) Introsnack kring Nyhetsmorgon och fetmakonferenser (00:08:14) Surmount 5 - Mounjaro vs Wegovy (Ozempic) (00:36:50) Outro - GBs nya policy om max 250 kalorier per glass

This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright break down the latest science behind GLP-1 medications like Ozempic, Wegovy, and Mounjaro. Dr. Cooper shares her decades of expertise on how these drugs work, their evolution, and whether you really have to take them for life. The episode dives deep into the individual factors that impact tapering off, the importance of metabolic signals (like famine and security signals), and why medication is just one piece of the metabolic puzzle. Key Takeaways:GLP-1 medications have advanced significantly, with more convenient dosing and greater effectiveness for many—but responses vary widely from patient to patient.Weight on the scale isn't the only measure; body composition, nutrient levels, and metabolic markers are critical in determining treatment and possible tapering.Not everyone needs to take GLP-1s forever—tapering is possible, but it depends on individual health markers, genetics, and whether metabolic signals are balanced.The future of metabolic health lies in combination therapies that target multiple pathways, not just GLP-1s.Dieting alone disrupts metabolic signals, making professional metabolic medicine and nutrition guidance essential for long-term health.Resources:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org or dr.c@fatsciencepodcast.com.Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

Do the collection of new weight loss drugs offer more than just weight loss? With claims suggesting that they can help lower risks of cancer and improve mood, Giles feels like he is missing out. Is it time for him to tuck in to Mounjaro? Esther is not convinced and if Giles and his peers live to be one hundred and forty, where are all the Gen Z's going to live?If you're lucky enough to come by a luxury copy of Jane Austen's ‘Emma' you may find a handy readers guide; “this novel may not be easy or enjoyable.” What else needs a handy guide – GCSE geography, home cooking, sex?After an oxbow lake via some noises that annoy a quick theatre recommendation for a farce of a play about spies… Readers guide: May contain innuendo and slapstick. Hosted on Acast. See acast.com/privacy for more information.

There is an abundance of data on the impact of coffee drinking on health. Dr. Lisa shares the data on the way coffee impacts our risk for premature death, diabetes, depression, heart disease, stroke, Parkinson's disease, dementia, and other health conditions. She also dives in to the impact of coffee on weight loss, of course. And for those taking GLP1 agonists like Wegovy or Ozempic (or GLP/GIP meds like Zepbound or Mounjaro), she reviews the data on coffee and sarcopenia, which is muscle loss.This episode is filled with myth busting surprises about coffee and health. Of course there are downsides to coffee, so if you're pregnant, or you find that coffee causes palpitations, worsening anxiety, or insomnia for you, then it's probably time to rethink your drink or cut down on your coffee. Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you (and those you love) improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! The challenges for people taking GLP-1s. (1:10) GLP-1s do NOT cause muscle loss. (3:10) The under-muscled epidemic. (5:48) The way GLP-1s work and what they do. (7:45) Obesity vs. under muscled. (11:12) Losing muscle is bad. How do you stop that from happening when on a GLP-1? #1 - Titrate the dose if too strong. Why you should go through a compound pharmacy. (13:30) #2 - Eat high protein. (16:49) #3 - Lift daily. (20:32) #4 - Drink ½ to 1 gallon of water daily. (24:18) #5 - Use essential amino acids, creatine, electrolytes, HMB. (25:42) Related Links/Products Mentioned Special Promotion: MAPS GLP-1 50% off!! ** Code 50OFFGLP1 at checkout ** Visit Seed for an exclusive offer for Mind Pump listeners! **Promo code 25MINDPUMP at checkout for 25% off your first month's supply of Seed's DS-01® Daily Synbiotic** Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Visit Transcend for this month's exclusive Mind Pump offer! ** 25% off all GLP-1s – This includes the GLP-1 probiotic which people can order through their specialist. ** Mind Pump #2360: What You Need to Know About GLP-1 With Dr. Tyna Moore Mind Pump #2110: Ozempic the Miracle Fat Loss Peptide: The Truth With Dr. William Seeds Mind Pump #2410: How to Maximize Fat Loss & Preserve Muscle on GLP-1s (Introducing MAPS GLP-1) Mind Pump #2432: The Truth About Essential Amino Acids with Angelo Keely HMB benefits, dosage, and side effects - Examine Mind Pump Podcast – YouTube Mind Pump Free Resources    

After being obliterated by the side effects of Mounjaro, Wippa told us that he has sworn off the drug but apparently he has been sneaking a poke in once a week and has found a brand new side effect...See omnystudio.com/listener for privacy information.

Have you lost a significant amount of weight and now feel stuck with the extra skin?You're not alone—and today's episode of Plastic Surgery Uncensored dives into that very struggle. With weight loss medications like Ozempic and Mounjaro gaining popularity, more people are achieving major weight loss—but many are left with loose, hanging skin that can't be fixed with diet or exercise alone. Dr. Rady Rahban is joined by his inspiring patient, Katie, who lost over half her body weight and underwent a circumferential body lift to reclaim her body and confidence. Katie opens up about her emotional weight loss journey, the reality behind obesity stigma, and why she finally turned to medication after years of yo-yo dieting. Dr. Rahban explains what a body lift entails, the recovery process, and how this surgery can be a life-changing step in a massive weight loss journey—both physically and mentally. Whether you've battled with weight or know someone who has, this episode is a must-listen. Now streaming on your favorite podcast platforms.Instagram: @DrRadyRahbanFacebook: @RadyRahbanMDWebsite: radyrahban.com

Afslankmedicijnen vliegen als warme broodjes over de toonbank. In een farmaceutische afvalrace strijden Eli Lilly en Novo Nordisk om het beste medicijn. Sinds kort lijkt Eli Lilly de beste kaarten in handen te hebben. In hoeverre helpen die medicijnen nou echt overgewicht de wereld uit? En hoe afhankelijk is het bedrijf inmiddels geworden van het afslankmiddel Mounjaro? Marco Frenken, country manager van Eli Lilly Nederland is te gast in BNR Zakendoen. Macro met Mujagić/Boot Elke dag een intrigerende gedachtewisseling over de stand van de macro-economie. Op maandag en vrijdag gaat presentator Thomas van Zijl in gesprek met econoom Arnoud Boot, de rest van de week praat Van Zijl met econoom Edin Mujagić. Ook altijd terug te vinden als je een aflevering gemist hebt. Blik op de wereld Wat speelt zich vandaag af op het wereldtoneel? Het laatste nieuws uit bijvoorbeeld Oekraïne, het Midden-Oosten, de Verenigde Staten of Brussel hoor je iedere werkdag om 12.10 van onze vaste experts en eigen redacteuren en verslaggevers. Ook los te vinden als podcast. Lobbypanel Culturele organisaties moeten langer subsidie krijgen. En kan de premie verplichte verzekering voor zelfstandigen tegen arbeidsongeschiktheid omlaag? Dat en meer bespreken we in het lobbypanel met: - Nora van Elferen, partner bij EPPA - Debbie de Wagenaar, reputatiemanager voor bedrijven Luister l Lobbypanel | Zakenlunch Elke dag, tijdens de lunch, geniet je mee van het laatste zakelijke nieuws, actuele informatie over de financiële markten en ander economische actualiteiten. Op een ontspannen manier word je als luisteraar bijgepraat over alles wat er speelt in de wereld van het bedrijfsleven en de beurs. En altijd terug te vinden als podcast, mocht je de lunch gemist hebben. Contact & Abonneren BNR Zakendoen zendt elke werkdag live uit van 11:00 tot 13:30 uur. Je kunt de redactie bereiken via e-mail. Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper. Biopharma reaction was one of tentative relief, with BMO Capital Markets analysts suggesting the executive order had “more bark than bite.” Meanwhile, the Centers for Medicare and Medicaid Services announced that among the next 15 drugs to undergo IRA-prescripted price negotiations could be drugs payable through Medicare Part B, and not just Part D, where the first two rounds have applied.  Into all of this action steps Vinay Prasad, the outspoken oncologist and hematologist who was named last week as the next director of the FDA's Center for Biologics Evaluation and Research. While the S&P Biotech ETF fell by more than 5% upon the news, overall reaction was fairly measured, with cell and gene therapy executive Audrey Greenberg summing up Prasad's selection as “anything but a status quo appointment.”  Over in the weight loss and obesity space, Eli Lilly can't seem to lose. This weekend, Lilly announced full data from a head-to-head trial showing a “superior benefit-to-risk ratio” for its Zepbound over Novo Nordisk's Wegovy. And last week, the Indiana-based pharma won a court battle against compounders when a judge sided with the FDA, stating that tirzepatide—the active ingredient in both Zepbound and diabetes sister drug Mounjaro—was no longer in shortage. Add on a presidential shoutout during Trump's Monday press conference for its U.S. manufacturing investments, and it really was Lilly's week.  Flying less high are some 2,000 Bayer employees who lost their jobs in the first quarter of 2025 as part of the company's new operating model, which is intended to make Bayer “much more agile.” On a less direct flight is Galapagos, which reversed course on plans to spin out a portion of the company and find a new CEO. Instead, CEO Paul Stoffels will make a quicker exit and the Belgian biotech could sell off its cell therapy assets as it looks to build up a new pipeline in house, having abandoned the spinout idea altogether. Stay tuned.  Finally, in ClinicaSpace this week, we took a deep dive into the HIV treatment space, where companies like Gilead and Immunocore are targeting a cure, while the Trump administration slashes funding for HIV research.  

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity.  

Stock markets rally as US and China agree to slash tariffs for at least 90 days. Also: Kurdish PKK militants end armed struggle against Turkey and Mounjaro and Wegovy go head to head in weight loss trial.

In this week's episode, we're taking a closer look at the sneaky side of nutrition—starting with hidden sugar. From yoghurt and oat milk to savoury sauces and baby food, we reveal just how much sugar is lurking in everyday items—and why it's so hard to spot on the label. Weight loss jabs like Ozempic and Mounjaro are still dominating headlines, but behind the hype lies a deeper conversation about self-worth, body image, and how 90s diet culture continues to shape our thinking. We share a powerful reflection from Elizabeth Day on the inner critic, societal pressure, and what true body neutrality looks like in 2025. We also break down the latest ultra-processed food research, including shocking new stats on early death risk. Are UPFs as dangerous as the data suggests—and what can we actually do about it? Plus, the baby food pouch scandal has reignited debate about infant nutrition. We unpack the findings, the marketing spin, and why transparency is urgently needed in this space. Elsewhere, Rhi reveals the surprising truth about plastics in activewear, Ella shares her take on the “bed rotting” trend, and we answer a listener question on the best ways to cook your veg without losing nutrients. Reccomendations: Crash Diets Don't Work - listen to Rhi's excellent reminder in the ep Weight loss jabs and the struggle for self-acceptance - a fascinating article from Elizabeth Day's Substack Email your MP via the Save The Children website to help protect foreign aid, urgently needed by mothers and newborn children across 12 countries. Live Show Tickets - https://cadoganhall.com/whats-on/the-wellness-scoop-with-ella-mills-and-rhiannon-lambert/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

La familia Real de Catar regaló a Donald Trump un lujoso avión valorado en más de 400 millones de dólares.En otras noticias: Con una nueva orden ejecutiva el presidente Trump espera reducir entre el 30% y 80% el precio de los medicamentos recetados. ¿Qué tan viable es?El Departamento de Seguridad Nacional inició una investigación para verificar si el condado de Los Ángeles proporcionó desde el 2021beneficios a personas indocumentados.Un juez federal autorizó que IRS comparta información fiscal confidencial con las autoridades migratorias para ayudar a localizar y deportar a inmigrantes indocumentados bajo investigación criminal.Hamás liberó al soldado estadounidense-israelí Edan Alexander.Comenzó el juicio contra Sean Diddy Combs en Nueva York en medio de escabrosas declaraciones. 

Os medicamentos injetáveis para emagrecimento, conhecidos como “canetas emagrecedoras”, incluindo Ozempic, Wegovy, Saxenda, Mounjaro e similares vinham sendo vendidos livremente no Brasil, sem a necessidade de prescrição médica. Mas isso vai mudar.A Agência Nacional de Vigilância Sanitária (Anvisa) aprovou uma nova regra para a venda desses medicamentos, que só poderá ser feita mediante apresentação de receita médica em duas vias, sendo que uma delas ficará retida na farmácia - procedimento semelhante ao já adotado para antibióticos.Neste episódio, conversamos sobre as indicações desses medicamentos, seus efeitos colaterais e a importância do acompanhamento médico para o uso correto.Links relacionados:Tirzepatide as Compared with Semaglutide for the Treatment of ObesityComida Sem Filtro #88 – Injetáveis Para EmagrecerComida Sem Filtro #146 – Ozempic: Como Evitar O Reganho De Peso?Comida Sem Filtro #125 – Efeito Ozempic Na Indústria De AlimentosEstamos no Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Souto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sari Fontana⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Para ser avisado sobre cada novo episódio e receber os links das matérias mencionadas e as referências bibliográficas por e-mail, cadastre-se gratuitamente em ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drsouto.com.br/podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira seu livro - UMA DIETA ALÉM DA MODA: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (também na versão Kindle)"Dance of the Sugar Plum Fairy"Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://creativecommons.org/licenses/by/3.0/⁠

Morse code transcription: vvv vvv Caught red handed Policing the men buying sex on Bristols streets De minimis changes I freaked out and spent 400 online Trump administration considering suspending habeas corpus Cardinal reveals what it was like to be part of conclave to choose Pope Leo Kyiv ceasefire talks mark a significant moment, says Starmer Taylor Swift criticises being pulled into Lively Baldoni row Labour to unveil big immigration plans next week but will they win back votes WeightWatchers bankruptcy Why weight loss injections like Mounjaro are hurting diet industry First time buyers Tips from those whove made it on to the housing ladder India and Pakistan accuse each other of violations after ceasefire deal

Morse code transcription: vvv vvv Trump administration considering suspending habeas corpus Cardinal reveals what it was like to be part of conclave to choose Pope Leo Kyiv ceasefire talks mark a significant moment, says Starmer WeightWatchers bankruptcy Why weight loss injections like Mounjaro are hurting diet industry Taylor Swift criticises being pulled into Lively Baldoni row India and Pakistan accuse each other of violations after ceasefire deal First time buyers Tips from those whove made it on to the housing ladder Caught red handed Policing the men buying sex on Bristols streets Labour to unveil big immigration plans next week but will they win back votes De minimis changes I freaked out and spent 400 online

Morse code transcription: vvv vvv Caught red handed Policing the men buying sex on Bristols streets Kyiv ceasefire talks mark a significant moment, says Starmer De minimis changes I freaked out and spent 400 online First time buyers Tips from those whove made it on to the housing ladder WeightWatchers bankruptcy Why weight loss injections like Mounjaro are hurting diet industry Cardinal reveals what it was like to be part of conclave to choose Pope Leo Taylor Swift criticises being pulled into Lively Baldoni row Trump administration considering suspending habeas corpus Labour to unveil big immigration plans next week but will they win back votes India and Pakistan accuse each other of violations after ceasefire deal

Morse code transcription: vvv vvv India and Pakistan accuse each other of violations after ceasefire deal Cardinal reveals what it was like to be part of conclave to choose Pope Leo Caught red handed Policing the men buying sex on Bristols streets Trump administration considering suspending habeas corpus Taylor Swift criticises being pulled into Lively Baldoni row Kyiv ceasefire talks mark a significant moment, says Starmer Labour to unveil big immigration plans next week but will they win back votes WeightWatchers bankruptcy Why weight loss injections like Mounjaro are hurting diet industry De minimis changes I freaked out and spent 400 online First time buyers Tips from those whove made it on to the housing ladder

Dave Knapp is a patient-turned-advocate in the field of GLP1 medications, obesity, and type 2 diabetes. He is the creator of "On the Pen," a fast-growing media platform that serves as a hub for breaking news and advocacy related to these pivotal areas. Through his extensive research and engagement with the subject, Dave has built a thriving online community focused on increasing awareness and access to life-changing GLP1 treatments. His insightful work has been featured in major outlets including Fortune, Bloomberg, and Yahoo Finance. Dave is also the author of the book "Decoding GLP1," offering a comprehensive guide to these medications. He resides in Washington, D.C., where he continues his advocacy work.Please learn more about David Knapp at www.GLPbook.comIn this episode of Mr. Biz Radio, Ken" Mr.Biz" Wentworth delves into the subject of GLP1 medications, obesity, and type 2 diabetes with guest Dave Knapp, a leading advocate in the field. The discussion revolves around how these medications are transforming lives by providing new treatment avenues for those battling obesity and type 2 diabetes. Dave shares his personal journey from being a patient to becoming a dedicated advocate, offering listeners a unique insider's perspective on the topic.Dave Knapp explains the science behind GLP1 medications, highlighting their role in mimicking naturally occurring hormones that impact insulin secretion and appetite control. He dispels common myths, emphasizing the long-standing presence of these drugs in the medical field. The conversation also covers the side effects associated with GLP1s, the variations in their effectiveness based on individual health profiles, and provides actionable insights into optimizing their use for better health outcomes.Key Takeaways:-These medications mimic naturally occurring hormones that are crucial in appetite control and insulin secretion, offering hope for patients with obesity and type 2 diabetes.-Dave Knapp turned to advocacy after his personal battle with obesity and type 2 diabetes, culminating in the creation of the "On the Pen" media platform.-A major misconception is that GLP1 medications are only for diabetes. They are also prescribed for obesity management.-New generations of GLP1 drugs like Mounjaro and Wegovy show substantial promise with less muscle mass loss when combined with lifestyle changes.-Dave Knapp's book "Decoding GLP1" provides invaluable information from a patient's perspective for those seeking to understand these medications better.

Morse code transcription: vvv vvv India strikes how will Pakistan respond Four key questions Israeli embassy in London was suspected terror plot target, BBC understands Nine arrested over Hitler birthday party in Oldham pub Liam Payne left behind 24m fortune without making a will Interest rates Cut expected by the Bank of England Joe Biden Trump is not behaving like a Republican president Man stabbed to death in Derby bank named Weightwatchers files for bankruptcy as Ozempic and Mounjaro surge in popularity The wedding with almost 100 bridesmaids Sycamore Gap felling bit of a laugh to accused, says prosecutor

Morse code transcription: vvv vvv The wedding with almost 100 bridesmaids Weightwatchers files for bankruptcy as Ozempic and Mounjaro surge in popularity Nine arrested over Hitler birthday party in Oldham pub Joe Biden Trump is not behaving like a Republican president India strikes how will Pakistan respond Four key questions Man stabbed to death in Derby bank named Liam Payne left behind 24m fortune without making a will Israeli embassy in London was suspected terror plot target, BBC understands Interest rates Cut expected by the Bank of England Sycamore Gap felling bit of a laugh to accused, says prosecutor

Morse code transcription: vvv vvv Nine arrested over Hitler birthday party in Oldham pub Man stabbed to death in Derby bank named Liam Payne left behind 24m fortune without making a will Joe Biden Trump is not behaving like a Republican president Israeli embassy in London was suspected terror plot target, BBC understands India strikes how will Pakistan respond Four key questions Sycamore Gap felling bit of a laugh to accused, says prosecutor The wedding with almost 100 bridesmaids Interest rates Cut expected by the Bank of England Weightwatchers files for bankruptcy as Ozempic and Mounjaro surge in popularity

Morse code transcription: vvv vvv Israeli embassy in London was suspected terror plot target, BBC understands Interest rates Cut expected by the Bank of England Nine arrested over Hitler birthday party in Oldham pub India strikes how will Pakistan respond Four key questions Man stabbed to death in Derby bank named Liam Payne left behind 24m fortune without making a will Weightwatchers files for bankruptcy as Ozempic and Mounjaro surge in popularity Sycamore Gap felling bit of a laugh to accused, says prosecutor Joe Biden Trump is not behaving like a Republican president The wedding with almost 100 bridesmaids

Driveway Beers PodcastBig Weight Loss News!!We're back talking about weight loss. Mike and Alex talk about where their weight is with the first part of Spring behind us. Was there weight loss or weight gain and what's the plan moving forward? The fellas have some big news to share in this one! Please subscribe and rate this podcast on your podcast platforms like Apple and Spotify as it helps us a ton. Also like, comment, subscribe and share the video on Youtube. It really helps us get the show out to more people. We hope you enjoyed your time with us and we look forward to seeing you next time. Please visit us at https://drivewaybeerspodcast.com/donate/ to join The Driveway Club and buy us a bourbon! Buy us a bottle and we'll review it on a show!Leave us a comment and join the conversation on our discord at https://discord.gg/rN25SbjUSZ.Please visit our sponsors:Adam Chubbuck of Team Alpha Charlie Real Estate, 8221 Ritchie Hwy, Pasadena, MD 21122, www.tacmd.com, (443) 457-9524. If you want a real estate agent that will treat your money like it's his own and provide you the best service as a buyer or seller, contact Adam at Team Alpha Charlie.If you want to sponsor the show, contact us at contact@drivewaybeerspodcast.comCheck out all our links here https://linktr.ee/drivewaybeerspodcast.comIf you're looking for sports betting picks, go to conncretelocks.com or send a message to Jeremy Conn at Jconn22@gmail.comFacebook Page https://www.facebook.com/drivewaybeerspodcast/#podcast #whiskey #bourbon

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

Dr. Sasha High, Internal Medicine and Obesity Medicine physician, breaks down a common patient question: which GLP-1 medication is best for weight management? On today's episode, we review data for Ozempic (Semaglutide), Wegovy (Semaglutide 2.4mg) and Mounjaro (Tirzepatide) for obesity treatment. We discuss: Weight loss efficacy Blood sugar control for Type 2 diabetes Cardiovascular outcomes Other conditions such as chronic kidney disease and sleep apnea Most relevant to the Canadian consumer is the discussion around insurance coverage and practical considerations like monthly cost. Reminder that you still need to speak with your own healthcare provider about what treatment is most appropriate for you and this is for educational purposes only. If you're in Ontario and need support from a multidisciplinary team for chronic weight management, The High Metabolic Clinic is my program that offers holistic virtual care from obesity specialists, registered dietitians and psychotherapists across Ontario through telemedicine. You can get more info at www.highmetabolicclinic.com. We do need a referral from your Family Doctor.

Medications like Ozempic, Wegovy, and Mounjaro are rapidly rising in popularity—not just among those managing type 2 diabetes, but also among people seeking significant weight loss. Once intended purely for blood sugar control, these weekly injections have now become a go-to solution for weight management, with some reports suggesting that 1 in 10 women in the UK are currently using them.But are they the game-changer they're claimed to be? While these medications offer real hope to those struggling with obesity or diabetes, there's still a lot to unpack. Are they truly safe? What are the potential downsides? And what should you be aware of if you're already using them—or considering it?In this episode, I explore:✔️ How GLP-1 medications like Ozempic, Wegovy and Mounjaro work✔️ What to expect if you're on one of these jabs✔️ Common side effects and potential health risks✔️ The importance of nutrition, movement and mindset to minimise risks and get the best results✔️ How to naturally stimulate your GLP-1 hormones through diet and lifestyleWhether you're on the jabs or not, if you're looking for support do contact us for more info; https://happyhormonesforlife.com/contact

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Lilly's revenue jumped by 45% in the latest quarter, driven by the success of their drugs Zepbound and Mounjaro. Moderna missed revenue expectations for the first quarter but plans to cut $1.5 billion in costs. Biogen executives are dealing with tariffs, but believe the impact will be minimal. The Department of Health and Human Services announced a new policy requiring placebo-controlled trials for all new vaccines, which has been met with criticism from experts. Trilink Biotechnologies has introduced custom sets of mRNA for screening studies. In other news, CVS has chosen Novo's side in the obesity market battle, RFK Jr. is sparking controversy in vaccine discussions, and J&J has entered the myasthenia gravis market. Additionally, AstraZeneca faced a setback with their drug Truqap in a phase III prostate cancer study.

CVS announces major partnership with Novo Nordisk as Lilly announces Q! 2025 earnings. Dave covers it all in today's breakdown. Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️

Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️

It seems like we all have patients taking Semaglutide or Tirzepatide and in this episode Tom Viola breaks down the things we need to know. How does it act? What should we be on the look our for? What oral/systemic manifestations might there be? Be sure to give this short episode a listen! Resources: Be sure to reach out to him if you have any questions by emailing TomViola@tomviola.com, visit his website TomViola.com or check out his social media - @pharmacologydeclassified

In this week's episode, Brooke and I are sharing a replay of our recent training on GLP-1 medications like Ozempic, Wegovy, and Mounjaro.

In this first part of a two-part series, Dr. Saluja and Kane unpack how GLP-1 and GIP medications, including Ozempic, Wegovy, and Mounjaro, are reshaping not just metabolism, but also facial structure, leading to what's now known as "Ozempic Face." In this episode, they explore what GLP-1 receptor agonists and GIP agonists are, how rapid fat loss affects skin, collagen, and volume, and introduce key strategies that can be done at home from a nutritional perspective to support collagen health and overall facial balance. Join them as they break down the science and lay the foundation for more advanced treatment approaches discussed in Part Two. Thank you for your listenership!

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. GLP-1 medications like Mounjaro are transforming the conversation around weight loss and diabetes management, but behind the headlines and medical jargon lies a real journey—one that's often emotional, confusing, and filled with misconceptions.In this episode, Dave Knapp, the visionary behind OnThePen.com and the voice of @manonthemounjaro, shares his personal journey with type 2 diabetes and Mounjaro. As someone deeply passionate about reshaping the conversation around GLP-1, obesity, and diabetes, Dave offers valuable insights and heartfelt personal stories.Join us as we explore the inspiration behind his book, Decoding GLP-1, where Dave breaks down the complexities of GLP-1 medications and shares practical tips for those supporting loved ones on this journey. Learn how to start stigma-free conversations, connect with a supportive community, and understand why there's no one-size-fits-all solution when it comes to managing obesity.ReferencesDecoding GLP-1 OnThePen.com@manonthemounjaroAudio Stamps01:11 - Dave Knapp shares how his type 2 diabetes journey and Mounjaro experience sparked the creation of On The Pen.03:20 - We learn why Dave wrote his “Decoding GLP-1” book—a quick, accessible guide to help loved ones understand GLP-1 meds and reduce the shame around sharing your story.07:52 -  Dr. Rentea asks how to start honest, stigma-free conversations with loved ones about using GLP-1 medication, especially when shame has made it hard to open up.12:58 - Dave and Dr. Rentea discuss the best ways to start finding a supportive community.19:32 - Dave offers his top tips for anyone getting started on this journey—and reminds us why there's no one-size-fits-all approach to treating obesity.Quotes“The people that have the best voice in this space have a personal experience with it.” - Dr. Rentea“It broke my heart to hear so many people afraid to share the part of their journey with the people that mattered the most.” - Dave Knapp“I could see not only family and friends reading this, but actually physicians giving this to their patients because people need it in one area like this.” - Dr. Rentea“Weight is cosmetic to the rest of the world. They don't see your A1C, they don't see your lipid panel, they don't see your fatty liver. But the reduction of those things is quite a story to tell. “Couching everything aroundAll of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Premium Season 1 of The Obesity Guide: Behind the Curtain -Dive into real clinical scenarios, from my personal medication journey to tackling weight loss plateaus, understanding insulin resistance, and overcoming challenges with GLP-1s. Plus, get a 40+ page guide packed with protein charts, weight loss formulas, and more. April 30/30 registration.

Ozempic, Mounjaro, Semaglutide, Retatrutide, and other GLP-1 agonist drugs are becoming more popular in bodybuilding.  In today's podcast I discuss why, the pros and cons of these drugs, and how to mitigate the negative impacts.

✨ My GLP-1 Girlie group program is opening again at the end of February for enrollment for a 3/2/25 start date.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it's not approved for T1D and so insurers won't usually cover it.   https://clinicaltrials.gov/study/NCT06914895 XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there's little information on the drugs' safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can't make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1.   For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what's really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html   XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA.  Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA's caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. https://tcoyd.org/petition/ XX Dexcom receives FDA approval for it's G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says    “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.   https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long   XX Glucotrack is joining something called  FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.   The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms.     Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr   XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, Illinois.     The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. https://www.news-medical.net/news/20250414/Digital-lifestyle-program-cuts-diabetes-risk-by-4625-in-prediabetics-study-of-130k2b-adults-reveals.aspx XX Chrissy Teigan is speaking out about her son's type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes.   Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!”   Teigen shared her family's story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles' diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” https://www.fiercepharma.com/marketing/sanofi-signs-chrissy-teigen-diabetes-screening-campaign XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein's Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”.  He practiced and saw patients right up until his death.

Des is turning 50, good at languages and bad at math, nostalgic humor, Des's drastic Mounjaro weight loss and subsequent constipation, Tay watching Severance = Des smoking weed, how Des and Hannah make time away work and their open relationship with comedy, the effect an IVF doc had on Des, the building collapsed during recordingDescription:Boll & Branch: Get 15% off plus free shipping on your first set of sheets at BollAndBranch.com with promo code TAYLORTrade Coffee: Get 50% Off Your One Month Trial with Trade, at drinktrade.com/taylorQuince: Quince.com/taylor for 365-day returns, plus free shipping on your orderDraftKings: Sign up with code TOT and wager a minimum of five dollars to receive FIVE HUNDRED CASINO SPINS ON A FEATURED GAME.Produced by Dear Media. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Elle Russ chats with Dr. Gary E. Foresman MD to unpack the science, hype, and controversy surrounding GLP-1-based weight loss medications like Ozempic, Wegovy, Mounjaro, and peptides. Dr. Foresman explores how these drugs actually work—from appetite suppression to metabolic effects—and who's a good candidate (and who should avoid them). The conversation tackles the real benefits and the real risks beyond the headlines - breaks down the differences between peptides and FDA-approved medications, and examines the big question: Is the weight loss sustainable long-term? We also dive into practical concerns like cost, accessibility, and alternatives for those seeking options outside this class of drugs. Whether you're considering these medications, curious about the science, or just tired of the hype, this conversation cuts through the noise with an honest, no-industry-spin look at one of the biggest health trends of our time. Article mentioned in this episode: https://www.middlepathmedicine.com/blogs/new-2024-articles-teachings/tirzepatide-the-time-has-come     SELECTED LINKS: https://www.elleruss.com/ https://www.middlepathmedicine.com/

Get your free 15-minute Rapid Nutrition Assessment to identify your biggest nutrition challenge and get a personalized action plan to optimize your approach, whether you're considering GLP-1s, currently using them, or transitioning off (or go to witsandweights.com and click "Free Nutrition Audit")--Millions of people are experiencing dramatic weight loss results with GLP-1 medications like Ozempic, Wegovy, and Mounjaro, but there's a catch that many doctors aren't discussing: without the right approach, up to 40% of that weight loss could be coming from muscle, not fat.This episode gives you a blueprint for maximizing the benefits of these medications while protecting your metabolism, strength, and long-term results. Today I'm sharing practical, evidence-based strategies to preserve muscle while maximizing fat loss on these powerful appesite-suppressing medications, including how to adjust your nutrition, training, and lifestyle to maintain those results even after you stop.Main Takeaways:GLP-1 medications aid weight loss primarily through appetite suppressionMuscle loss isn't caused by the medications but by rapid weight loss without interventionResistance training and sufficient protein intake are non-negotiable for preserving muscle massPlan your transition off medication well in advance with a strategic approachEpisode Resources:Try MacroFactor for free with code WITSANDWEIGHTSTimestamps: 0:01 - Understanding GLP-1 medications and body composition6:29 - Protein and nutrition strategies10:14 - Micronutrients and tracking calories12:10 - Why resistance training is essential16:02 - Managing energy levels and strength training16:47 - Planning for reducing or coming off GLP-1 medications21:56 - Body recompositionSupport the show

SPONSOR: Turtle Beach - Level up your game and get 10% off @TurtleBeach with code CHUBBY at https://www.turtlebeach.com/CHUBBY   BONUS EPISODES: https://www.Patreon.com/chubbybehemoth   This week the boys are in Embassy Suites in Lexington Kentucky (the good one!). Nathan is more Mounjaro than person, thinks about DDTing a child on the reg, and must have been getting laid when A Goofy Movie came out. Sam wonders what Venom smells like, accidentally bullied a man for three years, and tells us about going to Disneyland.   Nathan Lund and Sam Tallent are Chubby Behemoth   Mutiny Coffee: mutinyonmainstreet@gmail.com

Judy Greer (Arrested Development, Marvel's Ant-Man, 13 Going on 30, Halloween Kills) and Mayim relive the now legendary "Wil Wheaton fiasco", reminisce about THE BIG BANG THEORY (the role Judy continues to be recognized for most today) and their shared love for pickles and Taylor Swift! Judy reveals her powerful journey through perimenopause, from her symptoms and what encouraged her to seek help, to hormones and what has worked for her. She opens up about her body image & self-esteem issues, her thoughts on GLP-1 drugs (Ozempic, Mounjaro, Wegovy) and its effect on the body positivity movement. Judy discusses using alcohol as a reward and to ease social anxiety, sobriety and what it's taught her about herself, her codependent tendencies, religion's role in processing grief, and how she finds ways to decompress after a particularly traumatic acting role. Mayim and Judy bond over their love of Taylor Swift! Judy recounts her Eras Tour experience and how Folklore made her a “Swiftie.” PLUS, she explains why her mom got fired from being a nun and why playing the "best friend" is her go-to role. Don't miss this raw and inspiring chat! Check out ERIC LARUE in theaters on April 04, 2025!: https://www.fandango.com/eric-larue-2025-239640/movie-overview BialikBreakdown.comYouTube.com/mayimbialik

Comedian and writer Mariah Smith (Smith Sisters Live) joins Nicole to share some truly wild dating stories, including a guy who got horny discussing Black Lives Matter, and another who cried about his ex on the first date. She talks about her experience using an Instagram matchmaking service, and dishes out a hot tip for boosting your matches on dating apps. Plus, they try to settle the great iPhone vs. Android green bubble debate, and open up about their experiences losing over 100 lbs with Mounjaro.Watch this episode on YouTube to see our cute outfits! https://youtu.be/tU8d4azX5fIWrite to Nicole! Send your dirty messages to whywontyoudatemepodcast@gmail.com with the subject line "Dirty Message" and Nicole may read it in a future episode.To support this podcast, check out our sponsors & get discounts:» Alma: There's no replacement for human connection. Better with people. Better with Alma. Visit helloalma.com/DATEME to get started and schedule a free consultation today.» OneSkin: Get 15% off OneSkin with the code DATEME at oneskin.co #oneskinpod» SquareSpace: Head to squarespace.com/DATEME to save 10% off your first purchase of a website or domain using code DATEME.» ZocDoc: Stop putting off those doctors appointments and go to Zocdoc.com/DATEME to find and instantly book a top-rated doctor today.View all of our sponsors and discounts codes at wwydm.notion.site/sponsors.Follow:YouTube: @WhyWontYouDateMePodcastTikTok: @whywontyoudatemepod Instagram: @nicolebyerX: @nicolebyerNicole's book, #VERYFAT #VERYBRAVE: indiebound.org/book/9781524850746This is a Headgum podcast. Follow Headgum on Twitter, Instagram, and Tiktok. Advertise on Why Won't You Date Me? via Gumball.fm.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.